Caxton Associates LP Macrogenics Inc Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $51,797 - $116,891	11,562 New	11,562 $111,000
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $494,016 - $806,252	-106,930 Reduced 88.54%	13,838 $74,000
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $340,238 - $511,064	-70,589 Reduced 36.89%	120,768 $865,000
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $307,383 - $642,376	-92,031 Reduced 32.48%	191,357 $1.28 Million
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $799,994 - $1.39 Million	265,779 Added 1509.34%	283,388 $981,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $39,620 - $175,913	17,609 New	17,609 $52,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.